The Critical Path Institute

The Critical Path Institute, doing business as C-Path, is a tax-exempt nonprofit organization that operates as a federal research and development recipient, developing drug development tools, clinical outcome assessment frameworks, and regulatory science resources for the Food and Drug Administration and other federal health agencies. C-Path holds no federal contracts as a prime contractor through traditional contracting vehicles; instead, it receives definitive contracts and cooperative agreement grants directly from FDA centers and the Defense Health Agency to conduct applied research in clinical phenotyping, biomarker qualification, patient-reported outcome measure development, and medical product development standardization.

Headquartered in Tucson, Arizona, C-Path operates as a nonprofit public-private partnership with FDA and functions as a convening and research organization within the federal regulatory science ecosystem rather than as a traditional government contractor. The organization does not compete under set-aside designations; its federal funding flows directly through research and development awards and cooperative agreements with health agencies. C-Path's recent federal award portfolio is dominated by the Food and Drug Administration, which accounts for approximately 89% of awards and the full share of potential value across recent funding. The vendor works with nine distinct federal agencies, including the Defense Health Agency, the Center for Drug Evaluation and Research, and the Center for Biologics Evaluation and Research, reflecting a concentrated healthcare and regulatory-science customer base.

C-Path's capability footprint centers on developing and qualifying clinical outcome assessment tools, patient-reported outcome measures, and biomarker frameworks to support FDA regulatory submissions and drug development. Recent representative work includes a $3.375 million definitive contract awarded August 2024 by FDA to develop clinical phenotyping frameworks, biomarker landscape analysis, and patient identification tools for autosomal dominant tubulointerstitial kidney disease (ADTKD), with performance through August 2028 and subcontract support from Wake Forest University Health Sciences on biobanking and longitudinal biomarker analysis. C-Path received a $4.418 million definitive contract in September 2022 from FDA under Broad Agency Announcement EETWP #63 to develop a standardized framework supporting FDA qualification of complex in vitro models for regulatory submissions, completed September 2026. The organization also serves as prime recipient on multiple cooperative agreements with FDA's Center for Drug Evaluation and Research, including qualification package development for the Pediatric Asthma Diary-Child and Pediatric Asthma Diary-Observer (awarded September 2025, completion August 2027), the Virtual Reality Functional Capacity Assessment Tool for Alzheimer's disease (awarded September 2024, completion August 2027), the Chronic Heart Failure Symptom Scale (awarded September 2024, completion August 2027), and the Diary for Irritable Bowel Syndrome Symptoms–Diarrhea (awarded April 2024, completion March 2026).

Federal activity shows growth trajectory into FY2025, with seven awards in 2024 and one in 2025; four awards (combined potential value $3.4 million) face ultimate completion within the next twenty-four months. Combined obligated dollars across all awards total $266 million against $14.7 million in combined potential value, reflecting the organization's model of long-term cooperative agreements with incremental funding and obligation patterns typical of FDA research partnerships. SCI-reported invoicing on federal service contracts captured $1.1 million (FY2022) through $2.6 million (FY2025), with FY2025 showing 8.3 FTEs across SCI-reportable contracts. Government-paid rates on federal services run a median of $107.93 per hour, with senior labor rates reaching $136.95 per hour at the 90th percentile. Across SCI-reportable prime contracts, 16 percent of contractor hours are subcontracted; the organization maintains five named subcontractor relationships, including Johns Hopkins University on observational data integration for pregnant women and neonates. C-Path operates as a prime recipient on 97 percent of its federal awards, with only one grant sub-award (to Johns Hopkins University in February 2024). The organization's non-prime role is minimal; it functions as a direct federal research partner and convener rather than as a subordinate team member on larger prime awards.